When Business and Science Clash, How Can We Avoid Harming Patients?: The Case of AVOID-HF.
Publication
, Journal Article
Mark, DB; O'Connor, CM
Published in: JACC Heart Fail
February 2016
Duke Scholars
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
February 2016
Volume
4
Issue
2
Start / End Page
106 / 108
Location
United States
Related Subject Headings
- Treatment Outcome
- Humans
- Heart Failure
- Diuretics
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Mark, D. B., & O’Connor, C. M. (2016). When Business and Science Clash, How Can We Avoid Harming Patients?: The Case of AVOID-HF. JACC Heart Fail, 4(2), 106–108. https://doi.org/10.1016/j.jchf.2015.09.001
Mark, Daniel B., and Christopher M. O’Connor. “When Business and Science Clash, How Can We Avoid Harming Patients?: The Case of AVOID-HF.” JACC Heart Fail 4, no. 2 (February 2016): 106–8. https://doi.org/10.1016/j.jchf.2015.09.001.
Mark DB, O’Connor CM. When Business and Science Clash, How Can We Avoid Harming Patients?: The Case of AVOID-HF. JACC Heart Fail. 2016 Feb;4(2):106–8.
Mark, Daniel B., and Christopher M. O’Connor. “When Business and Science Clash, How Can We Avoid Harming Patients?: The Case of AVOID-HF.” JACC Heart Fail, vol. 4, no. 2, Feb. 2016, pp. 106–08. Pubmed, doi:10.1016/j.jchf.2015.09.001.
Mark DB, O’Connor CM. When Business and Science Clash, How Can We Avoid Harming Patients?: The Case of AVOID-HF. JACC Heart Fail. 2016 Feb;4(2):106–108.
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
February 2016
Volume
4
Issue
2
Start / End Page
106 / 108
Location
United States
Related Subject Headings
- Treatment Outcome
- Humans
- Heart Failure
- Diuretics
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology